Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
JD Health International, Inc. ( (HK:6618) ) has issued an announcement.
JD Health International, Inc. announced amendments to its existing agreements with JD.com, including changes to the Promotional Campaign Services Framework Agreement and the Shared Services Framework Agreement. The company has set new annual caps for these agreements for the year ending December 31, 2025, and has renewed the agreements for a three-year term starting January 1, 2026. These transactions are considered continuing connected transactions under the Listing Rules, with some requiring compliance with specific provisions. The company has also received a waiver from strict compliance with certain listing rule requirements, indicating strategic adjustments in its operational agreements with JD.com, which could impact its market positioning and stakeholder relationships.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$78.50 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
More about JD Health International, Inc.
JD Health International, Inc. operates in the healthcare industry, focusing on providing online healthcare services and products. The company is a subsidiary of JD.com, a major e-commerce company, and is involved in promoting health-related services and products through digital platforms.
Average Trading Volume: 9,992,197
Technical Sentiment Signal: Buy
Current Market Cap: HK$206.5B
Learn more about 6618 stock on TipRanks’ Stock Analysis page.